In addition, peptidoglycan (PGN), PLK inhibitors (BI 2536, BI 6727, and GSK461364), and propofol (an anesthetic agent) were found to inhibit AKT3 and may be potential candidates for CRC therapeutic regimens57–59. This evidence concerns the gene AKT3 and colorectal carcinoma.